insights_auto
Why is KYNB up ၂.၅၂%?
Dive Deeperchevron_right
KYNB:NASDAQ
Kyntra Bio Inc
၆.၁၁ US$
arrow_upward
+၂.၅၂%(+၀.၁၅) 1D
အောက် ၉, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KYNB...
Open
၆.၀၈ US$
High
၆.၂၆ US$
Low
၆.၀၈ US$
Mkt. cap
၂.၄၇ ကုဋေ
Avg. vol.
၂.၅၈ သောင်း
Volume
၃.၀၀
P/E ratio
၀.၁၃
52-wk high
၉.၇၀ US$
52-wk low
၅.၆၂ US$
EPS
၄၅.၃၀ US$
Beta
၁.၀၅
Shares outstanding
၄.၀၅ သန်း
No. of employees
၃၄
Open
၆.၀၈ US$
High
၆.၂၆ US$
Low
၆.၀၈ US$
Mkt. cap
၂.၄၇ ကုဋေ
Avg. vol.
၂.၅၈ သောင်း
Volume
၃.၀၀
P/E ratio
၀.၁၃
52-wk high
၉.၇၀ US$
52-wk low
၅.၆၂ US$
EPS
၄၅.၃၀ US$
Beta
၁.၀၅
Shares outstanding
၄.၀၅ သန်း
No. of employees
၃၄
News stories
From web sources and news partners
Yahoo Finance
·
ပြီးခဲ့သည့် ၁ နာရီ
Why Are Nasdaq Futures Rising Premarket? MU, IREN, SLS, NIO, ASTS, WFF Stocks In Focus
Sahi
·
ပြီးခဲ့သည့် ၅၃ မိနစ်
Black Box Shows Interest In Nasdaq Listed Aeries Technology Reporting $70 Million FY26 Revenue
The Motley Fool
·
ပြီးခဲ့သည့် ၁၈ မိနစ်
Vanguard's S&P 500 Fund Has Raised Its Payout 71% Since 2016. Its Yield Has Nearly Halved.
Bloomberg.com
·
ပြီးခဲ့သည့် ၁ နာရီ
Oil Rises on Mideast Attacks, Dollar Edges Higher: Markets Wrap
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
About Kyntra Bio Inc
CEO-
Employees၃၄
Founded၁၉၉၃ ဇန် ၁
Headquartersဆန်ဖရန်စစ္စကိုမြို့, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitekyntrabio.com